Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
boston blog main
7
×
boston top stories
life sciences
national blog main
national top stories
biotech
clinical trials
fda
indiana blog main
indiana top stories
san francisco blog main
san francisco top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
alexion pharmaceuticals
boston
deals
eli lilly
sanofi
abbvie
amyotrophic lateral sclerosis (als)
boehringer ingelheim
congress
gene therapy
gilead sciences
What
pharma
7
×
drug
medicines
bio
deal
dicerna
disease
executives
pharmaceuticals
roundup
abandoning
abbvie’s
administration
ago
ahead
alternative
angry
anti
autoimmune
away
baggage
benefited
biofourmis
biopharma
bringing
bucks
cancer
candidate
caught
causing
celebrate
ceos
chance
companies
congress
congressional
corner
crispr
cuts
day
Language
unset
Current search:
photo
×
pharma
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M